Austin, TX – According to filings with the U.S. Securities and Exchange Commission, 4e Therapeutics is raising $2,000,020.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Benson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 4e Therapeutics
4E Therapeutics is dedicated to developing innovative and novel treatments for neuropathic pain. 4E Therapeutics is a developer of novel therapeutics designed to treat chronic pain disorders, such as neuropathic pain. The companys therapeutics include orally-bioavailable MNK inhibitors with improved tissue-specificity and pharmacokinetic profiles that has potent analgesic activity in multiple animal pain models, enabling doctors to use the drugs for targeting the activity of the elF4E proteins, in an effort to regulate the activity of pain-sensing neurons in the peripheral nervous system.

To learn more about 4e Therapeutics, visit http://4etherapeutics.com/

Contact:
Thomas Benson, Chief Executive Officer
512-577-7779

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved